Publications

• Rodseeda C, Yamanont P, Pinthong D, Korprasertthaworn P*. Inhibitory effects of Thai herbal extracts on the cytochrome P450 3A-mediated the metabolism of gefitinib, lapatinib and sorafenib. Toxicol Rep 2022;9;1846-52.
• Korprasertthaworn P, Chau N, Nair PC, Rowland A, Miners JO. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202. Biochem Pharmacol. 2019;169:113616.
• Jampasri S, Reabroi S, Tungmunnithu, D, Parichatikanond W, Korprasertthaworn P, Pinthong D. Plumbagin exerts anticancer activity by suppressing HIF-1α expression under hypoxic condition in MCF-7 breast cancer cells. Proceedings of the 41st Pharmacological and Therapeutic Society of Thailand Meeting. Chiang Mai University, Thailand. 2019(PH-033):73-8.
• Polasek TM, Tucker GT, Sorich MJ, Wiese MD, Mohan T, Rostami-Hodjegan A, Korprasertthaworn P, Perera V, Rowland A. Prediction of olanzapine exposure in individual patients using physiologically-based pharmacokinetic modelling and simulation. Br J Clin Pharmacol. 2018;84(3):462-76.
• Lewis BC, Korprasertthaworn P, Miners JO. Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variantsof CYP1A1 and CYP1A2: implications for cancer therapy. Pharmacogenet Genomics. 2016;26(10):453-61.
• Korprasertthaworn P, Polasek TM, Sorich MJ, McLachlan AJ, Miners JO, Tucker GT, et al. In vitro characterization of human liver microsomal kinetics and enzyme involvement in olanzapine metabolism. Drug Metab Dispos. 2015;43(11):1806-14.
• Korprasertthaworn P, Rowland A, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochem Pharmacol. 2012;84(11):1511-21.
• Korprasertthaworn P, Udomuksorn W, Yoovathaworn K. Three novel single nucleotide polymorphisms of UGT1A9 in a Thai population. Drug Metab Pharmacokinet. 2009;24(5): 482-5.